A cross-laboratory preclinical study on the effectiveness of interleukin-1 receptor antagonist in stroke

Journal of Cerebral Blood Flow and Metabolism

Volumn 36, Issue 3, 2016, Pages 596-605

  Maysami, Samaneh ^a   Wong, Raymond ^a   Pradillo, Jesus M ^a,b   Denes, Adam ^a,c   Dhungana, Hiramani ^d   Malm, Tarja ^d   Koistinaho, Jari ^d   Orset, Cyrille ^e   Rahman, Mahbubur ^f,g   Rubio, Marina ^e   Schwaninger, Markus ^f   Vivien, Denis ^e   Bath, Philip M ^h   Rothwell, Nancy J ^a   Allan, Stuart M ^a  

^a UNIVERSITY OF MANCHESTER   (United Kingdom)

^b UNIVERSIDAD COMPLUTENSE DE MADRID   (Spain)

^c INSTITUTE OF EXPERIMENTAL MEDICINE   (Hungary)

^d UNIVERSITY OF EASTERN FINLAND   (Finland)

^e UNIVERSITÉ DE CAEN   (France)

^f UNIVERSITY OF LÜBECK   (Germany)

^g NORTH SOUTH UNIVERSITY   (Bangladesh)

^h UNIVERSITY OF NOTTINGHAM   (United Kingdom)

Author keywords

Acute stroke; animal models; experimental; inflammation; neuroprotection

Indexed keywords

INTERLEUKIN 1 RECEPTOR BLOCKING AGENT; PLACEBO; INTERLEUKIN 1 RECEPTOR; NEUROPROTECTIVE AGENT;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; BRAIN EDEMA; BRAIN SIZE; CONTROLLED STUDY; DRUG EFFICACY; EUROPE; EXPERIMENTAL STROKE; MALE; MIDDLE CEREBRAL ARTERY OCCLUSION; MORTALITY; MOUSE; NEUROPROTECTION; NONHUMAN; NUCLEAR MAGNETIC RESONANCE IMAGING; PRIORITY JOURNAL; ANIMAL; ANTAGONISTS AND INHIBITORS; BAGG ALBINO MOUSE; BRAIN; BRAIN ISCHEMIA; C57BL MOUSE; COMPLICATION; DISEASE MODEL; DRUG EFFECTS; IMMUNOLOGY; INFLAMMATION; PATHOLOGY; PRECLINICAL STUDY; STROKE;

ANIMALS; BRAIN; BRAIN EDEMA; BRAIN ISCHEMIA; DISEASE MODELS, ANIMAL; DRUG EVALUATION, PRECLINICAL; INFLAMMATION; INTERLEUKIN 1 RECEPTOR ANTAGONIST PROTEIN; MALE; MICE, INBRED BALB C; MICE, INBRED C57BL; NEUROPROTECTIVE AGENTS; RECEPTORS, INTERLEUKIN-1; STROKE;

EID: 84959323965     PISSN: 0271678X     EISSN: 15597016     Source Type: Journal    
DOI: 10.1177/0271678X15606714     Document Type: Article

References (21)

1. Stroke Association. Facts, and figures about stroke: 2003 Stroke Fact Sheet. www.stroke.org.uk/noticeboard/facts.html. (accessed 8 September 2015
2. Adamson JBA, and Ebrahim S. Is stroke the most common cause of disability?. J Stroke Cerebrovasc Dis 2004; 13: 171-177
3. Goyal M, Demchuk AM, Menon BK, et al. Randomized assessment of rapid endovascular treatment of ischemic stroke. New Engl J Med 2015; 372: 1019-1030
4. Fisher M, Feuerstein G, Howells DW, et al. Update of the stroke therapy academic industry roundtable preclinical recommendations. Stroke 2009; 40: 2244-2250
5. Dirnagl U, and Fisher M. International, multicenter randomized preclinical trials in translational stroke research: its time to act. J Cereb Blood Flow Metab 2012; 32: 933-935
6. Bath PMW, Macleod MR, and Green AR. Emulating multicentre clinical stroke trials: a new paradigm for studying novel interventions in experimental models of stroke. Int J Stroke 2009; 4: 471-479
7. Allan SM, Tyrrell PJ, and Rothwell NJ. Interleukin-1, and neuronal injury. Nat Rev Immunol 2005; 5: 629-640
8. Denes A, Thornton P, Rothwell NJ, et al. Inflammation, and brain injury: acute cerebral ischaemia, peripheral, and central inflammation. Brain Behav Immun 2010; 24: 708-723
9. Murray KN, Parry-Jones AR, and Allan SM. Interleukin-1, and acute brain injury. Front Cell Neurosci 2015; 9: 18
10. Pradillo JM, Denes A, Greenhalgh AD, et al. Delayed administration of interleukin-1 receptor antagonist reduces ischemic brain damage, and inflammation in comorbid rats. J Cereb Blood Flow, and Metab 2012; 32: 1810-1819
11. Greenhalgh AD, Brough D, Robinson EM, et al. Interleukin-1 receptor antagonist is beneficial after subarachnoid haemorrhage in rat by blocking haem-driven inflammatory pathology. Dis Model Mech 2012; 5: 823-833
12. Tehranian R, Andell-Jonsson S, Beni SM, et al. Improved recovery, and delayed cytokine induction after closed head injury in mice with central overexpression of the secreted isoform of the interleukin-1 receptor antagonist. J Neurotrauma 2002; 19: 939-951
13. Emsley HCA, Smith CJ, Georgiou RF, et al. A randomised phase II study of interleukin-1 receptor antagonist in acute stroke patients. J Neurol Neurosurg Psychiatry 2005; 76: 1366-1372
14. Hooijmans CR, and Ritskes-Hoitinga M. Progress in using systematic reviews of animal studies to improve translational research. Plos Med 2013; 10: e1001482
15. Kilkenny C, Browne WJ, Cuthill IC, et al. Improving bioscience research reporting: the ARRIVE guidelines for reporting animal research. Plos Biol 2010; 8: e1000412
16. Hunter AJ, Hatcher J, Virley D, et al. Functional assessments in mice, and rats after focal stroke. Neuropharmacology 2000; 39: 806-816
17. Bederson JB, Pitts LH, Tsuji M, et al. Rat middle cerebral artery occlusion: evaluation of the model, and development of a neurologic examination. Stroke 1986; 17: 472-476
18. Garcia JH, Wagner S, Liu KF, et al. Neurological deficit, and extent of neuronal necrosis attributable to middle cerebral-artery occlusion in rats -statistical validation. Stroke 1995; 26: 627-634
19. Stroke Therapy Academic Industry Roundtable II (STAIR-II). Recommendations for clinical trial evaluation of acute stroke therapies. Stroke 2001; 32: 1598-1606
20. DerSimonian R, and Laird N. Meta-analysis in clinical trials. Control Clin Trials 1986; 7: 177-188
21. Perel P, Roberts I, Sena E, et al. Comparison of treatment effects between animal experiments, and clinical trials: systematic review. Br Med J 2007; 334: 197-200